Early growth inhibition is followed by increased metastatic disease with vitamin D (Calcitriol) treatment in the TRAMP model of prostate cancer

PLoS ONE

Volumn 9, Issue 2, 2014, Pages

  Ajibade, Adebusola Alagbala ^a   Kirk, Jason S ^a   Karasik, Ellen ^a   Gillard, Bryan ^a   Moser, Michael T ^a   Johnson, Candace S ^a   Trump, Donald L ^a   Foster, Barbara A ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1ALPHA HYDROXYMETHYL 16 ENE 24,24 DIFLUORO 25 HYDROXY 26,27 BIS HOMOVITAMIN D3; ANDROGEN; CADHERIN; CADHERIN 1; CALCITRIOL; CALCITRIOL DERIVATIVE; UNCLASSIFIED DRUG; DIHYDROXY-VITAMIN D3; VITAMIN D;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CONTROL; CANCER INHIBITION; CANCER MODEL; CASTRATION RESISTANT PROSTATE CANCER; CHRONIC DRUG ADMINISTRATION; COHORT ANALYSIS; CONTROLLED STUDY; DISTANT METASTASIS; FEMALE; GROWTH INHIBITION; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PRIMARY TUMOR; PROSTATE WEIGHT; PROTEIN EXPRESSION; TREATMENT DURATION; UROGENITAL SYSTEM; ADENOCARCINOMA; ANALOGS AND DERIVATIVES; ANIMAL; C57BL MOUSE; CELL DIFFERENTIATION; CELL PROLIFERATION; DISEASE MODEL; DRUG EFFECTS; ENZYME IMMUNOASSAY; HUMAN; INCIDENCE; PATHOLOGY; PROSTATIC NEOPLASMS; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; SECONDARY; TRANSGENIC MOUSE; TUMOR CELL CULTURE; WESTERN BLOTTING;

ADENOCARCINOMA; ANIMALS; BLOTTING, WESTERN; CELL DIFFERENTIATION; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; HUMANS; IMMUNOENZYME TECHNIQUES; INCIDENCE; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; PROSTATIC NEOPLASMS; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; TUMOR CELLS, CULTURED; VITAMIN D;

EID: 84896258971     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0089555     Document Type: Article

References (51)

1. Siegel R, Naishadham D, Jemal A (2012) Cancer statistics, 2012. CA: a cancer journal for clinicians 62: 10-29.
2. Soloway M, Roach M, 3rd (2005) Prostate cancer progression after therapy of primary curative intent: a review of data from prostate-specific antigen era. Cancer 104: 2310-2322. (Pubitemid 41691551)
3. Klein EA (2006) Chemoprevention of prostate cancer. Annu Rev Med 57: 49-63.
4. Schwartz GG, Hulka BS (1990) Is vitamin D deficiency a risk factor for prostate cancer? (Hypothesis). Anticancer Res 10: 1307-1311.
5. Barnett CM, Nielson CM, Shannon J, Chan JM, Shikany JM, et al. (2010) Serum 25-OH vitamin D levels and risk of developing prostate cancer in older men. Cancer Causes Control 21: 1297-1303.
6. Getzenberg RH, Light BW, Lapco PE, Konety BR, Nangia AK, et al. (1997) Vitamin D inhibition of prostate adenocarcinoma growth and metastasis in the Dunning rat prostate model system. Urology 50: 999-1006. (Pubitemid 28021128)
7. Schwartz GG, Wang MH, Zang M, Singh RK, Siegal GP (1997) 1 alpha,25-Dihydroxyvitamin D (calcitriol) inhibits the invasiveness of human prostate cancer cells. Cancer Epidemiol Biomarkers Prev 6: 727-732. (Pubitemid 27427629)
8. Zhuang SH, Burnstein KL (1998) Antiproliferative effect of 1alpha,25-dihydroxyvitamin D3 in human prostate cancer cell line LNCaP involves reduction of cyclin-dependent kinase 2 activity and persistent G1 accumulation. Endocrinology 139: 1197-1207.
9. Guzey M, Kitada S, Reed JC (2002) Apoptosis induction by 1alpha,25-dihydroxyvitamin D3 in prostate cancer. Mol Cancer Ther 1: 667-677.
10. Hedlund TE, Moffatt KA, Uskokovic MR, Miller GJ (1997) Three synthetic vitamin D analogues induce prostate-specific acid phosphatase and prostate-specific antigen while inhibiting the growth of human prostate cancer cells in a vitamin D receptor-dependent fashion. Clin Cancer Res 3: 1331-1338. (Pubitemid 27362394)
11. Blutt SE, Polek TC, Stewart LV, Kattan MW, Weigel NL (2000) A calcitriol analogue, EB1089, inhibits the growth of LNCaP tumors in nude mice. Cancer research 60: 779-782. (Pubitemid 30129500)
12. Schwartz GG, Hill CC, Oeler TA, Becich MJ, Bahnson RR (1995) 1,25-Dihydroxy-16-ene-23-yne-vitamin D3 and prostate cancer cell proliferation in vivo. Urology 46: 365-369.
13. Banach-Petrosky W, Ouyang X, Gao H, Nader K, Ji Y, et al. (2006) Vitamin D inhibits the formation of prostatic intraepithelial neoplasia in Nkx3.1;Pten mutant mice. Clin Cancer Res 12: 5895-5901. (Pubitemid 44629623)
14. Perez-Stable CM, Schwartz GG, Farinas A, Finegold M, Binderup L, et al. (2002) The G gamma/T-15 transgenic mouse model of androgen-independent prostate cancer: target cells of carcinogenesis and the effect of the vitamin D analogue EB 1089. Cancer Epidemiol Biomarkers Prev 11: 555-563. (Pubitemid 34615163)
15. Osborn JL, Schwartz GG, Smith DC, Bahnson R, Day R, et al. (1995) Phase II trial of oral 1,25-dihydroxyvitamin D (calcitriol) in hormone refractory prostate cancer. Urol Oncol 1: 195-198.
16. Beer TM, Lemmon D, Lowe BA, Henner WD (2003) High-dose weekly oral calcitriol in patients with a rising PSA after prostatectomy or radiation for prostate carcinoma. Cancer 97: 1217-1224. (Pubitemid 36237307)
17. Beer TM, Garzotto M, Park B, Mori M, Myrthue A, et al. (2006) Effect of calcitriol on prostate-specific antigen in vitro and in humans. Clin Cancer Res 12: 2812-2816.
18. Liu G, Oettel K, Ripple G, Staab MJ, Horvath D, et al. (2002) Phase I trial of 1alpha-hydroxyvitamin d(2) in patients with hormone refractory prostate cancer. Clin Cancer Res 8: 2820-2827. (Pubitemid 35025725)
19. Gross C, Stamey T, Hancock S, Feldman D (1998) Treatment of early recurrent prostate cancer with 1,25-dihydroxyvitamin D3 (calcitriol). J Urol 159: 2035-2039; discussion 2039-2040.
20. Beer TM, Ryan CW, Venner PM, Petrylak DP, Chatta GS, et al. (2007) Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: a report from the ASCENT Investigators. J Clin Oncol 25: 669-674. (Pubitemid 350002922)
21. Posner GH, Lee JK, Wang Q, Peleg S, Burke M, et al. (1998) Noncalcemic, antiproliferative, transcriptionally active, 24-fluorinated hybrid analogues of the hormone 1alpha,25-dihydroxyvitamin D3. Synthesis and preliminary biological evaluation. J Med Chem 41: 3008-3014. (Pubitemid 28359936)
22. Alagbala A, Johnson CS, Trump DL, Posner GH, Foster BA (2006) Antitumor effects of less-calcemic vitamin D analogs (paricalcitol and QW-1624F2-2) in squamous cell carcinoma (SCC) cells. Oncology 70: 483-492. (Pubitemid 46333770)
23. Kensler TW, Dolan PM, Gange SJ, Lee JK, Wang Q, et al. (2000) Conceptually new deltanoids (vitamin D analogs) inhibit multistage skin tumorigenesis. Carcinogenesis 21: 1341-1345. (Pubitemid 30455993)
24. Greenberg NM, DeMayo F, Finegold MJ, Medina D, Tilley WD, et al. (1995) Prostate cancer in a transgenic mouse. Proc Natl Acad Sci U S A 92: 3439-3443.
25. Kaplan-Lefko PJ, Chen TM, Ittmann MM, Barrios RJ, Ayala GE, et al. (2003) Pathobiology of autochthonous prostate cancer in a pre-clinical transgenic mouse model. Prostate 55: 219-237. (Pubitemid 36532401)
26. Gingrich JR, Barrios RJ, Kattan MW, Nahm HS, Finegold MJ, et al. (1997) Androgen-independent prostate cancer progression in the TRAMP model. Cancer Res 57: 4687-4691. (Pubitemid 27468967)
27. Raghow S, Hooshdaran MZ, Katiyar S, Steiner MS (2002) Toremifene prevents prostate cancer in the transgenic adenocarcinoma of mouse prostate model. Cancer Res 62: 1370-1376. (Pubitemid 34407794)
28. Raghow S, Kuliyev E, Steakley M, Greenberg N, Steiner MS (2000) Efficacious chemoprevention of primary prostate cancer by flutamide in an autochthonous transgenic model. Cancer Res 60: 4093-4097. (Pubitemid 30636590)
29. Gingrich JR, Barrios RJ, Morton RA, Boyce BF, DeMayo FJ, et al. (1996) Metastatic prostate cancer in a transgenic mouse. Cancer Res 56: 4096-4102. (Pubitemid 26304996)
30. Aberle H, Schwartz H, Kemler R (1996) Cadherin-catenin complex: protein interactions and their implications for cadherin function. Journal of cellular biochemistry 61: 514-523. (Pubitemid 26240128)
31. Campbell MJ, Elstner E, Holden S, Uskokovic M, Koeffler HP (1997) Inhibition of proliferation of prostate cancer cells by a 19-nor-hexafluoride vitamin D3 analogue involves the induction of p21waf1, p27kip1 and E-cadherin. J Mol Endocrinol 19: 15-27. (Pubitemid 27345239)
32. Getzenberg RH, Light BW, Lapco PE, Konety BR, Nangia AK, et al. (1997) Vitamin D inhibition of prostate adenocarcinoma growth and metastasis in the Dunning rat prostate model system. Urology 50: 999-1006. (Pubitemid 28021128)
33. Lokeshwar BL, Schwartz GG, Selzer MG, Burnstein KL, Zhuang SH, et al. (1999) Inhibition of prostate cancer metastasis in vivo: a comparison of 1,23-dihydroxyvitamin D (calcitriol) and EB1089. Cancer Epidemiol Biomarkers Prev 8: 241-248. (Pubitemid 29114202)
34. Schwartz GG, Wang MH, Zang M, Singh RK, Siegal GP (1997) 1 alpha,25-Dihydroxyvitamin D (calcitriol) inhibits the invasiveness of human prostate cancer cells. Cancer epidemiology, biomarkers & prevention: a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 6: 727-732.
35. Sung V, Feldman D (2000) 1,25-Dihydroxyvitamin D3 decreases human prostate cancer cell adhesion and migration. Molecular and cellular endocrinology 164: 133-143. (Pubitemid 30665507)
36. Rankin W, Grill V, Martin TJ (1997) Parathyroid hormone-related protein and hypercalcemia. Cancer 80: 1564-1571. (Pubitemid 27444028)
37. Iwamura M, di Sant'Agnese PA, Wu G, Benning CM, Cockett AT, et al. (1993) Immunohistochemical localization of parathyroid hormone-related protein in human prostate cancer. Cancer Res 53: 1724-1726. (Pubitemid 23127091)
38. Dehm SM, Tindall DJ (2006) Molecular regulation of androgen action in prostate cancer. J Cell Biochem 99: 333-344. (Pubitemid 44435552)
39. Kurita T, Wang YZ, Donjacour AA, Zhao C, Lydon JP, et al. (2001) Paracrine regulation of apoptosis by steroid hormones in the male and female reproductive system. Cell Death Differ 8: 192-200. (Pubitemid 32201366)
40. Leman ES, Arlotti JA, Dhir R, Getzenberg RH (2003) Vitamin D and androgen regulation of prostatic growth. J Cell Biochem 90: 138-147. (Pubitemid 37052316)
41. Nelson WJ, Nusse R (2004) Convergence of Wnt, beta-catenin, and cadherin pathways. Science 303: 1483-1487. (Pubitemid 38314410)
42. Umbas R, Schalken JA, Aalders TW, Carter BS, Karthaus HF, et al. (1992) Expression of the cellular adhesion molecule E-cadherin is reduced or absent in high-grade prostate cancer. Cancer Res 52: 5104-5109.
43. Feldman BJ, Feldman D (2001) The development of androgen-independent prostate cancer. Nat Rev Cancer 1: 34-45. (Pubitemid 33741879)
44. Han G, Foster BA, Mistry S, Buchanan G, Harris JM, et al. (2001) Hormone status selects for spontaneous somatic androgen receptor variants that demonstrate specific ligand and cofactor dependent activities in autochthonous prostate cancer. J Biol Chem 276: 11204-11213. (Pubitemid 38089305)
45. Konety BR, Schwartz GG, Acierno JS, Jr., Becich MJ, Getzenberg RH (1996) The role of vitamin D in normal prostate growth and differentiation. Cell Growth Differ 7: 1563-1570. (Pubitemid 26378351)
46. Osborne JL, Schwartz GG, Smith DC, Bahnson R, Day RS, et al. (1995) Phase II trial of oral 1,25-dihydroxyvitamin D (calcitriol) in hormone refractory prostate cancer. Urol Oncol 1: 195-198.
47. Beer TM, Ryan CW, Venner PM, Petrylak DP, Chatta G, et al. Interim results from ASCENT: A double-blinded randomized study of DN-101 (high-dose calcitriol) plus docetaxel vs. placebo plus docetaxel in androgen-independent prostate cancer (AIPC); 2005 June 1, 2005. pp. 4516.
48. Trump DL, Potter DM, Muindi J, Brufsky A, Johnson CS (2006) Phase II trial of high-dose, intermittent calcitriol (1,25 dihydroxyvitamin D3) and dexamethasone in androgen-independent prostate cancer. Cancer 106: 2136-2142. (Pubitemid 43673234)
49. Scher HI, Jia X, Chi K, de Wit R, Berry WR, et al. (2011) Randomized, open-label phase III trial of docetaxel plus high-dose calcitriol versus docetaxel plus prednisone for patients with castration-resistant prostate cancer. J Clin Oncol 29: 2191-2198.
50. Sakr WA, Haas GP, Cassin BF, Pontes JE, Crissman JD (1993) The frequency of carcinoma and intraepithelial neoplasia of the prostate in young male patients. J Urol 150: 379-385. (Pubitemid 23215874)
51. Bostwick DG, Liu L, Brawer MK, Qian J (2004) High-grade prostatic intraepithelial neoplasia. Rev Urol 6: 171-179.